Vancomycin MIC susceptibility testing of methicillin-susceptible and methicillin-resistant Staphylococcus aureus isolates: A comparison between Etest® and an automated testing method

Southern Medical Journal

Volumn 103, Issue 11, 2010, Pages 1124-1128

  Bland, Christopher M ^a   Porr, William H ^a   Davis, Kepler A ^a   Mansell, Karon B ^a  

^a EISENHOWER ARMY MEDICAL CENTER   (United States)

Author keywords

Etest; MIC; MRSA; MSSA; vancomycin

Indexed keywords

VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOMATED TESTING METHOD; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; DILUTION; EPSILOMETER TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SENSITIVE STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; SWEDEN;

AUTOMATION; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SOUTHEASTERN UNITED STATES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE; VANCOMYCIN RESISTANCE;

EID: 78549267117     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181efb5b1     Document Type: Article

References (23)

1. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. CLSI approved standard M100-S16. Wayne, PA, CLSI, 2006.
2. Chang S, Sievert DM, Hageman JC, et al; Vancomycin-Resistant Staph-ylococcus aureus Investigative Team. Infection with vancomycin-resis-tant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-1347.
3. Whitener CJ, Park SY, Browne FA, et al. Vancomycin-resistant Staph-ylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis 2004;38:1049-1055.
4. Charles PG, Ward PB, Johnson PD, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staph-ylococcus aureus. Clin Infect Dis 2004;38:448-451.
5. Fridkin SK, Hageman J, McDougal LK, et al; Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003;36:429-439.
6. Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004;38:1700-1705.
7. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC bactericidal activity to efficacy of vancomycin treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42: 2398-2402.
8. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200.
9. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of Staph-ylococci with reduced susceptibilities to vancomycin and other glyco-peptides. J Clin Microbiol 1998;36:1020-1027.
10. Hsu DI, Hidayat LK, Quist R, et al. Comparison of method-specific vancomycin inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 2008;32:378-385.
11. Prakash V, Lewis JS II, Jorgensen JH. Vancomycin MICs for methicil-lin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother 2008;52: 4258.
12. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimum inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007;44:1208-1215.
13. Infectious Diseases Society of America. FDA lowers vancomycin breakpoints for Staphylococcus aureus. https://www.idsociety.org/newsArticle. aspx?id= 11388. Accessed May 27, 2008.
14. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and tox-icity. Arch Intern Med 2006;166:2138-2144.
15. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315-3320.
16. Maclayton DO, Suda KJ, Coval KA, et al. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2μ g/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther 2006;28:1208-1216.
17. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm 2009;66:82-98.
18. Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003;82:333-339.
19. Fortún J, Navas E, Martínez-Beltrán J, et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin Infect Dis 2001;33:120-125.
20. Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by me-thicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29:1171-1177.
21. Rubio M, Romero J, Corral O, et al. Bacteremia by Staphylococcus aureus: analysis of 311 episodes [in Spanish]. Enferm Infecc Microbiol Clin 1999;17:56-64.
22. Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of Vancomycin or first-generation cephalosporins for the treatment of hemodialysis\dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007;44:190-196.
23. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethox-azole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992;117:390-398